Pipeline › tirzepatide › Zepbound

Zepbound

Zepbound is a brand of tirzepatide from Eli Lilly, first approved by the FDA on 2023-11-08 under application NDA217806, not separately authorised in the European Union under this name, with no open FDA supply records.

Zepbound is Eli Lilly's brand of tirzepatide, approved under NDA217806. The same molecule is also sold as Mounjaro — a separate application with its own approved uses and its own supply record, which is why the two are tracked apart here rather than merged. Its current FDA label, effective 2026-08-28, covers obesity, sleep apnea. Nothing under this name is currently on the FDA shortage list.

Zepbound and Mounjaro are the same molecule. They are marketed under separate FDA applications with different approved indications, so they are distinct products on the regulatory record even though the active ingredient is identical. Compare the applications below. Side by side: Zepbound vs Mounjaro.

Active ingredient

tirzepatide

Sponsor

Eli Lilly

FDA applications

NDA217806

First FDA action

2023-11-08

Most recent FDA action

2026-08-26

FDA actions on file

45

EU authorisation

Not under this name

Active trials of tirzepatide

99

Approved indications

Quoted from the current FDA label for each application. This is what the drug is approved to treat in the US — separate from the conditions it is being studied in.

FDA record

Every approved submission filed under this brand, newest first, from Drugs@FDA: original approval, efficacy supplements, labeling changes and manufacturing updates. New safety language usually arrives in a labeling supplement.

For the molecule behind this brand — every trial, every indication under study and the full research record — see tirzepatide.